Impact of Exercise and Diet on Kidney Health
Effects of an Exercise Program and a Protein Controlled Diet Using an Educational Intervention on Biochemical Parameters, Muscle Strength and Body Composition in Patients With Stage G1 and G2 CKD
This study tests if a structured exercise and diet program can help people with early-stage chronic kidney disease feel better and slow down the progression of their condition.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 15 (estimated) |
| Ages | 18 Years to 65 Years |
| Sex | All |
| Sponsor | University of Guadalajara Academic / other |
| Locations | 1 site (Ciudad Guzmán, Jalisco) |
| Trial ID | NCT06912425 on ClinicalTrials.gov |
What this trial studies
This study investigates how a structured exercise and diet program can improve health outcomes in patients with early-stage chronic kidney disease (CKD). It focuses on patients in stages G1 and G2, aiming to enhance adherence to treatment and promote healthy lifestyle changes. The intervention includes education on diet and exercise, which are expected to positively influence biochemical parameters and potentially delay disease progression. The study is conducted at Ciudad Guzmán Hospital and emphasizes the importance of non-pharmacological approaches in managing CKD.
Who should consider this trial
Good fit: Ideal candidates are adults aged 18 to 65 with a confirmed diagnosis of CKD in stages G1 or G2 and no limitations to exercise.
Not a fit: Patients with advanced CKD beyond stage G2 or those with severe comorbidities that prevent participation in exercise may not benefit from this study.
Why it matters
Potential benefit: If successful, this program could significantly improve the health and quality of life for patients with early-stage CKD.
How similar studies have performed: While exercise and diet interventions have shown promise in other populations, this specific approach in early-stage CKD is relatively novel and underexplored.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Established diagnosis of CKD by the physician in G1 and G2 * Who meet the requirements of normal or decreased filtration rate according to: * G1: ≥ 90 or G2: 60-89 mL/ min/ 1.73m2 * Alterations in the urinary sediment (cellular cylinders of any type, dysmorphic erythrocytes). * Confirmation of damage by renal ultrasound (Decreased renal size, thinning of the renal cortex, increased echogenicity of the parenchyma, poor differentiation between the renal cortex and sinus, renal cysts suggestive of cortical or medullary changes). * Men and women between 18 and 65 years old * Control of baseline pathologies (glycosylated hemoglobin less than 9%, blood pressure no higher than 140/90mmHg). * Patients who agree to participate in the study and sign the informed consent form. * Patients who have no limitations to perform the exercises. * If participants have diagnosed diabetes or hypertension, who are on medication and under regular internal medicine or nephrology treatment. * Male and female patients, including those who are illiterate but can be accompanied in the initial sessions to sign the informed consent form. * All participants, even those who do not have a mobile device, will be provided with an exercise and nutrition guide so that they do not have any limitations when carrying out the activities. Exclusion Criteria: * Stages 3, 4 and 5 * Children under 18 years of age * Patients who, due to their place of origin, find it difficult to travel to the sessions. * Diabetes Mellitus in uncontrolled (Glycated Hemoglobin \>9 %) * Those who have lost their sight * Presence of uremic alterations such as uremic encephalopathy. * Who present unstable blood pressure with blood pressure levels above 140/90mmHg, patients showing sustained blood pressure elevations above 140/90 will be discontinued from the study. * Peripheral vascular disease of all types (Peripheral Arterial Disease (PAD), Deep Vein Thrombosis (DVT), Chronic Venous Disease (CVD), Abdominal Aortic Aneurysm (AAA), Buerger's Phenomenon (Thromboangiitis Obliterans), Kawasaki Disease). * Failure to sign the informed consent form Elimination Criteria: * Injury, discomfort that makes reincorporation impossible. * Patients who have decided to abandon the study * Patients who do not attend 2 of the face-to-face sessions, those who do not attend two of their sessions will be taken into consideration.
Where this trial is running
Ciudad Guzmán, Jalisco
- Centro Universitario del Sur — Ciudad Guzmán, Jalisco, Mexico (Recruiting)
Study contacts
- Study coordinator: Ana Patricia Zepeda Salvador, PhD
- Email: ana.zepeda@cusur.udg.mx
- Phone: 341 575 2222
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.